A Small Molecule Angiotensin II Type 2 Receptor (AT2R) Antagonist Produces Analgesia in a Rat Model of Neuropathic Pain by Inhibition of p38 Mitogen-Activated Protein Kinase (MAPK) and p44/p42 MAPK Activation in the Dorsal Root Ganglia

Pain Medicine (United States)

Volumn 14, Issue 10, 2013, Pages 1557-1568

  Smith, Maree T ^a   Woodruff, Trent M ^a   Wyse, Bruce D ^a   Muralidharan, Arjun ^a   Walther, Thomas ^b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Analgesia; Angiotensin II; Dorsal Root Ganglia; Neuropathic Pain; P38 Mitogen Activated Protein Kinase (MAPK); P44 p42 MAPK

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCITONIN; DILMAPIMOD; EMA 300; LOSMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SUBSTANCE P; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL ROOT; FEMALE; GANGLION; GENE DELETION; GENOTYPE; HEMIZYGOTE; MALE; NERVE FIBER GROWTH; NEUROPATHIC PAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SENSORY NERVE CELL; SIGNAL TRANSDUCTION;

ANALGESIA; ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR (AT2R); DORSAL ROOT GANGLIA; NEUROPATHIC PAIN; P38 MITOGEN ACTIVATED PROTEIN KINASE (MAPK); P44/P42 MAPK;

ANALGESICS; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GANGLIA, SPINAL; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR SEQUENCE DATA; NEURALGIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84885856314     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12157     Document Type: Article

References (36)

1. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-581.
2. Zhang JM, Strong JA. Recent evidence for activity-dependent initiation of sympathetic sprouting and neuropathic pain. Sheng Li Xue Bao 2008;60:617-627.
3. Smith MT, Wyse BD, Edwards SR. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: Comparative pharmacokinetics, radioligand binding and efficacy in rats. Pain Med 2013;14:692-705.
4. Yu L, Shao C, Gao L. Developmental expression patterns for angiotensin receptors in mouse skin and brain. J Renin Angiotensin Aldosterone Syst 2012. doi: 101177/1470320312467557.
5. Anand U, Facer P, Yiangou Y, etal. Angiotensin II type 2 receptor (AT(2) R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 2012. doi: 101002/j1532-2149201200269x.
6. Kang J, Sumners C, Posner P. Modulation of net outward current in cultured neurons by angiotensin II: Involvement of AT1 and AT2 receptors. Brain Res 1992;580:317-324.
7. Chakrabarty A, Blacklock A, Svojanovsky S, Smith PG. Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. Endocrinology 2008;149:3452-3460.
8. Porrello ER, Delbridge LM, Thomas WG. The angiotensin II type 2 (AT2) receptor: An enigmatic seven transmembrane receptor. Front Biosci 2009;14:958-972.
9. Brillante DG, Johnstone MT, Howes LG. Effects of intravenous PD 123319 on haemodynamic and arterial stiffness indices in healthy volunteers. J Renin Angiotensin Aldosterone Syst 2005;6:102-106.
10. McCarthy TD, Desem N, Kitson G, etal. Clinical development of EMA401: An angiotensin II type 2 receptor antagonist as a potential new treatment for neuropathic pain. In: Tracey I, ed. Abstracts of the 14th World Congress on Pain. Milan, Italy: IASP Press; 2012:31.
11. Bautista D, Julius D. Fire in the hole: Pore dilation of the capsaicin receptor TRPV1. Nat Neurosci 2008;11:528-529.
12. Gendron L, Laflamme L, Rivard N, etal. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999;13:1615-1626.
13. Plouffe B, Guimond MO, Beaudry H, Gallo-Payet N. Role of tyrosine kinase receptors in angiotensin II AT2 receptor signaling: Involvement in neurite outgrowth and in p42/p44mapk activation in NG108-15 cells. Endocrinology 2006;147:4646-4654.
14. Hudmon A, Choi JS, Tyrrell L, etal. Phosphorylation of sodium channel Na(v)1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J Neurosci 2008;28:3190-3201.
15. Stamboulian S, Choi JS, Ahn HS, etal. ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. J Neurosci 2010;30:1637-1647.
16. Persson AK, Gasser A, Black JA, Waxman SG. Nav1.7 accumulates and co-localizes with phosphorylated ERK1/2 within transected axons in early experimental neuromas. Exp Neurol 2011;230:273-279.
17. Martin SW, Butcher AJ, Berrow NS, etal. Phosphorylation sites on calcium channel alpha1 and beta subunits regulate ERK-dependent modulation of neuronal N-type calcium channels. Cell Calcium 2006;39:275-292.
18. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68.
19. Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol 2008;64:644-653.
20. Anand P, Shenoy R, Palmer JE, etal. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 2011;15:1040-1048.
21. Kingwell K. Pain: MAPK inhibitor shows promise in clinical trial for neuropathic pain. Nat Rev Neurol 2011;7:360.
22. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87-107.
23. RR J. Mitogen-activated protein kinases as potential targets for pain killers. Curr Opin Investig Drugs 2004;5:71-75.
24. Obata K, Yamanaka H, Dai Y, etal. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur J Neurosci 2004;20:2881-2895.
25. Ostenfeld T, Krishen A, Lai RY, etal. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: A double-blind, placebo-controlled study. Eur J Pain 2013;17:844-857.
26. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): Stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009;15:369-379.
27. Obata K, Noguchi K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci 2004;74:2643-2653.
28. Guimond MO, Roberge C, Gallo-Payet N. Fyn is involved in angiotensin II type 2 receptor-induced neurite outgrowth, but not in p42/p44mapk in NG108-15 cells. Mol Cell Neurosci 2010;45:201-212.
29. Cote F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999;274:31686-31692.
30. Patil J, Schwab A, Nussberger J, etal. Intraneuronal angiotensinergic system in rat and human dorsal root ganglia. Regul Pept 2010;162:90-98.
31. Devor M. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp Brain Res 2009;196:115-128.
32. Craner MJ, Klein JP, Renganathan M, Black JA, Waxman SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol 2002;52:786-792.
33. Amir R, Argoff CE, Bennett GJ, etal. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006;7:S1-29.
34. Miao XR, Gao XF, Wu JX, etal. Bilateral downregulation of Nav1.8 in dorsal root ganglia of rats with bone cancer pain induced by inoculation with Walker 256 breast tumor cells. BMC Cancer 2010;10:216.
35. Anand P. Neurotrophic factors and their receptors in human sensory neuropathies. Prog Brain Res 2004;146:477-492.
36. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther 2010;12:94-106.